Genmab A/S (GNMSF) News Today $198.51 -6.49 (-3.17%) As of 07/3/2025 12:46 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock GNMSF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Genmab A/S (OTCMKTS:GNMSF) Share Price Passes Below 50 Day Moving Average - Time to Sell?July 3 at 5:18 AM | marketbeat.comGenmab Completes Share Buy-back ProgramJune 30, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Above Fifty Day Moving Average - Here's What HappenedJune 25, 2025 | marketbeat.comGenmab A/S (GNMSF) Stock Price, Quote, News & Analysis - Seeking AlphaJune 24, 2025 | seekingalpha.comGenmab A/S (OTCMKTS:GNMSF) Trading Down 4.9% - Here's What HappenedJune 18, 2025 | marketbeat.comGenmab A/S Updates Articles of Association for Strategic GrowthJune 18, 2025 | tipranks.comGenmab Discloses Managerial Share Transactions in Compliance with RegulationsJune 17, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Passes Above 50-Day Moving Average - Should You Sell?June 17, 2025 | marketbeat.comGenmab A/S Updates Articles of Association to Enhance Capital FlexibilityJune 16, 2025 | tipranks.comGenmab Executes Share Buy-back Transactions in June 2025June 16, 2025 | tipranks.comGenmab Advances Share Buy-back Program in June 2025June 10, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Above Fifty Day Moving Average - Time to Sell?June 6, 2025 | marketbeat.comASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive dataJune 4, 2025 | msn.comGenmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial CancerJune 3, 2025 | insidermonkey.comGenmab A/S (OTCMKTS:GNMSF) Short Interest UpdateJune 1, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50-Day Moving Average - Here's What HappenedMay 30, 2025 | marketbeat.comGenmab Executes Share Buy-back Transactions in May 2025May 27, 2025 | tipranks.comGenmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025May 24, 2025 | finance.yahoo.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above 50-Day Moving Average - Here's WhyMay 23, 2025 | marketbeat.comGenmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025May 23, 2025 | insidermonkey.comGenmab announces share buy-back transactionsMay 21, 2025 | investing.comGenmab A/S Updates Articles to Enhance Capital FlexibilityMay 21, 2025 | tipranks.comGenmab Executes Share Buy-back Transactions in May 2025May 19, 2025 | tipranks.comGenmab A/S: Transitioning From Royalty Model To Commercial-Stage OncologyMay 19, 2025 | seekingalpha.comGenmab Executes Share Buy-back Transactions in May 2025May 12, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Posts Earnings Results, Beats Expectations By $1.17 EPSMay 12, 2025 | marketbeat.comGenmab A/S: Genmab Announces Financial Results for the First Quarter of 2024May 10, 2025 | finanznachrichten.deGenmab Executes Share Buy-back Transactions in Early May 2025May 5, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Short Interest Up 30.1% in AprilMay 4, 2025 | marketbeat.comIs Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?May 1, 2025 | insidermonkey.comGenmab Continues Share Buy-back Program in April 2025April 28, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average - What's Next?April 26, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below 200 Day Moving Average - Here's WhyApril 17, 2025 | marketbeat.comGenmab Advances Share Buy-back Program with Significant TransactionsApril 14, 2025 | tipranks.comGenmab A/S Updates Articles of Association to Enhance Capital FlexibilityApril 10, 2025 | tipranks.comGenmab A/S Share Capital ReductionApril 10, 2025 | investing.comGenmab A/S (OTCMKTS:GNMSF) Hits New 12-Month Low - Here's What HappenedApril 10, 2025 | marketbeat.comGenmab A/S Advances Share Buy-back Program as of April 2025April 7, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Hits New 1-Year Low - Here's WhyApril 4, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average - What's Next?April 3, 2025 | marketbeat.comIs Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?April 2, 2025 | insidermonkey.comGenmab Discloses Managerial Share TransactionsApril 1, 2025 | tipranks.comGenmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent ConcernsApril 1, 2025 | tipranks.comGenmab’s Tivdak approved in Japan for advanced cervical cancerMarch 28, 2025 | msn.comGenmab A/S Updates Articles of Association to Enhance Financial FlexibilityMarch 20, 2025 | tipranks.comGenmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trialMarch 17, 2025 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?March 13, 2025 | marketbeat.comGenmab price target lowered to DKK 2,300 from DKK 2,400 at RBC CapitalMarch 12, 2025 | markets.businessinsider.comGenmab A/S (0MGB) Gets a Buy from BarclaysMarch 12, 2025 | markets.businessinsider.comGenmab A/S Announces Board Constitution and Stock GrantsMarch 12, 2025 | tipranks.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Media Mentions By Week GNMSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼0.930.54▲Average Medical News Sentiment GNMSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼22▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today Daiichi Sankyo News Today argenex News Today BeOne Medicines News Today BioNTech News Today Teva Pharmaceutical Industries News Today Insmed News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Genmab A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
